Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$544.63 USD

544.63
358,441

-1.33 (-0.24%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $544.62 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

UpHealth, Inc. (UPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

UpHealth, Inc. (UPH) delivered earnings and revenue surprises of -525% and 18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ensign Group (ENSG) Rises 30% in 6 Months: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for improvement on growing revenues derived from catering to patients under Medicaid and Medicare programs. Solid cash flows are other tailwinds.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

ELV vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Cigna (CI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Cigna's (CI) stock price is increasing on the back of solid performances in the Evernorth and Cigna Healthcare businesses.

Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.

Humana (HUM) Rises 23% in Past 6 Months: More Room to Run?

by Zacks Equity Research

Humana (HUM) is well-poised for growth on improving revenues, numerous contract wins and adequate cash-generating abilities.

Acadia (ACHC) Reveals its Long-Term Goals: What You Should Know

by Zacks Equity Research

From 2022 to 2028, Acadia Healthcare (ACHC) expects to see a 9-11% CAGR in revenues.

The Joint (JYNT) Expands Operations to Alaska With 3 Clinics

by Zacks Equity Research

The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.

Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023

by Zacks Equity Research

Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in a bid to drive pharmacy revenues.

Centene (CNC) Concludes Magellan Rx Divestment to Prime

by Zacks Equity Research

Centene (CNC) completes Magellan Rx divestment within the scheduled time.

The Zacks Analyst Blog Highlights Apple, IBM, Elevance Health, Charter Communications and Archer-Daniels-Midland Company

by Zacks Equity Research

Apple, IBM, Elevance Health, Charter Communications and Archer-Daniels-Midland Company are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, IBM & Elevance Health

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), International Business Machines Corporation (IBM) and Elevance Health Inc. (ELV).

NextGen (NXGN) Buys TSI Healthcare to Boost Ambulatory Services

by Zacks Equity Research

NextGen (NXGN) acquires TSI Healthcare which may further solidify NXGN's position in the ambulatory healthcare space.

Humana (HUM) Ups '23 Medicare Advantage Membership Growth View

by Zacks Equity Research

Humana (HUM) expects 2023 net membership gains to be a minimum of 10.9% from the 2022 projection.

Why You Should Retain Centene (CNC) in Your Portfolio Now

by Zacks Equity Research

Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.

Patterson Companies (PDCO) Q2 Earnings Beat, Sales Hurt by FX

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter 2023 results reflect unfavorable currency movements.

Acadia (ACHC) JV Opens New Behavioral Health Unit in Fort Wayne

by Zacks Equity Research

The opening of the new hospital is in line with Acadia Healthcare's (ACHC) vision to bolster its reach in the U.S. behavioral healthcare market.

Derek Lewis headshot

3 Top-Ranked Large-Caps With Big Growth

by Derek Lewis

Large-cap stocks are a staple in every portfolio. They're well-established, have greater analyst coverage, typically pay dividends, and help shield investors from volatility.

What You Need to Know From UnitedHealth's (UNH) Latest Outlook

by Zacks Equity Research

UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.

Factors That Make Elevance Health (ELV) a Lucrative Bet Now

by Zacks Equity Research

Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.

ELV vs. PGNY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?

by Zacks Equity Research

Cigna (CI) expects its long-term adjusted earnings per share to witness 10-13% average annual growth.